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Vaccines intended to induce a cytotoxic CD8+ T-cell response are highly sought after. However, some of these vaccines can be
problematic if they replicate in the host. An alternative strategy is to exploit cross-presentation of exogenous antigens to express
peptides on major histocompatibility complex (MHC) class I molecules. During cross-presentation, the delivered exogenous
antigen can be taken up and processed through diverse mechanisms. Here, we will discuss the recent advances regarding the
complexnatureofthecross-primingprocessandthemodelsthatreﬂectitsrelevanceinvivo.Moreover,wesummarizecurrentdata
that explore potential adjuvants and vaccine vectors that deliver antigens to activate CD8+ T cells relying on cross-presentation.
1.Introduction
Na¨ ıve CD8+ T cells become activated when their recep-
tors recognize antigens presented by professional antigen-
presenting cells (pAPCs) in the context of MHC-I molecules.
Upon recognition of target cells, such primed cytotoxic T-
lymphocytes (CTLs) are able to limit the spread of virus
infection through the lysis of host-infected cells. Moreover,
alongwithhelperTcellstheyorchestratetheinductionofkey
cytokines such as interferon-γ (IFN-γ) and tumor necrosis
factor-α (TNF-α) needed for an optimal immune response
[1]. In addition to their importance in halting virus replica-
tion,CTLsplayacentralroleinthespeciﬁcimmuneresponse
andareessentialintheeliminationofintracellularpathogens
and limiting the potential escape of tumor cells [2, 3].
The cross-presentation pathway allows for exogenously-
derived antigens to be presented on MHC-I molecules to
CTLs [4–7]. To induce antitumor immune responses, or
to prime CTLs for viruses that inhibit direct presentation,
the immune system utilizes cross-presentation [8, 9]. Thus,
cross-presentation represents a promising mechanism for
strategies that target the induction of CTL responses for
vaccine development to induce both eﬀector and protective
memoryT-cellresponses.Inorderforustodiscusstheroleof
cross-presentation in future vaccine developments we need
to explore antigen presentation in details.
2. The MHC-IPresentationPathways
All nucleated cells express MHC-I molecules and are capable
ofpresentingantigenstoCTLs.However,the“priming”stage
or activation of na¨ ıve CD8+ T cells requires peptide-MHC
class I complexes presented by the pAPC in addition to co-
stimulatory signals such as interaction with B7 molecules,
CD40,CD70,andthe4-1BBLfamilymembers[10],aswellas
the secretion of key cytokines such as IL-12 and IFN-α [11–
13]. These cytokines are also important in optimal CD8+ T-
cells memory development [14] .T h eC D 8 +Tc e l l sp r i m i n g
step can occur via two diﬀerent mechanisms of antigen pre-
sentation:thedirect-andcross-presentationpathways.Inthe
direct or “endogenous” presentation pathway, antigens are
derived from endogenously synthesized proteins, improperly
translated proteins, and, or unstable defective ribosomal
proteins [15, 16]. These cytosolic proteins are targeted
for proteasomal degradation after their polyubiquination.
Proteasomal degradation products are then transported
into the endoplasmic reticulum (ER) via the transporter
associated with antigen processing (TAP), moving through
the Golgi complex to the cell surface (Figure 1).
Alternatively, the cross- or the “exogenous-” presen-
tation pathway occurs when uninfected pAPCs present
exogenously-derived antigens [4, 5, 7] after uptake of soluble













Figure 1: Antigen processing pathways. Direct presentation
involvestheprocessingofendogenouslysynthesizedantigens(route
A) by the proteasome (I) to break them down into smaller fragment
(polypeptides) that are transported through the transporter associ-
ated with antigen processing (TAP) into the endoplasmic reticulum
(II) for loading onto newly synthesized MHC class I molecules.
These peptide-loaded MHC class I molecules are then transported
through the Golgi (III) to the cell surface for presentation to
CD8+ T cells. Considering the major route for antigen cross-
presentation (route B), exogenous antigens are internalized in the
endosome/phagosome before they are released into the cytosol
and degraded by the proteasome to be presented on MHC class I
molecules.
be derived from diﬀerent sources such as cellular frag-
ments [17–19], intracellular bacteria [20], virus-infected or
tumor cells [21–26], and as reported recently from parasitic
infections [27]. It appears that protein stability in these
models is critical for eﬃcient cross-presentation to occur
[17, 28–31]. On the other hand, soluble proteins tend to be
cross-presented, but with much lower eﬃciency than cell-
associated proteins [32]. Although eﬃcient presentation of
exogenousantigens wasoriginallyattributedtomacrophages
[33], it is now clear that such function can be achieved by
diﬀerent bone marrow-derived APCs, including DCs and
macrophages[34–36],aswellasspleen-derivedmacrophages
[37]. Interestingly, it appears both spleen and bone marrow-
derived macrophages down regulate their ability to cross-
present cell-associated antigens during diﬀerentiation [37].
In cross-presentation, several processing mechanisms
have been proposed [38], including the canonical model
where antigens inside the endosomal/phagosomal vesicles
are translocated into the cytosol before they follow the
regular proteasome/ER/TAP route (Figure 1). In addition,
it was proposed that pAPCs possess organelles, such as
the phagosome, optimized for the cross-presentation of
exogenous antigens [38], by functioning autonomously to
generate MHC class I-peptide complexes from proteins
internalized into the same phagosome. Moreover, soluble
antigen cross-presentation was recently found to involve
early endocytic compartment traﬃcking that is aided by
TAP recruitment and signaling through TLR4 and MyD88
[39]. However, whether these antigen processing models are
applicable to exogenous antigens other than OVA proteins
has yet to be investigated.
3. Induction of Tolerance versus Priming
As this paper focuses on exogenous antigen delivery in vac-
cinedevelopment,wewillconcentrateoncross-presentation.
Regardless of the exact processing mechanism in play
within the cell, the cross-presentation pathway can result
in one of two outcomes: cross-tolerance or cross-priming.
Inadequate activation of CTLs may result in tolerance, which
is an ideal situation for self-antigens. Thus, under normal
circumstances, cross-presentation of peripheral self-antigens
from normal healthy tissue will induce cross-tolerance [40,
41]. This outcome could depend on many factors such as
which APC is presenting the antigen [41–43], and how the
antigen is being cross-presented [44, 45]. On the other hand,
if immunity is to be induced, signals necessary for T-cell
activation [46] leading to cross-priming will be provided
by pAPCs, leading to clonal expansion, diﬀerentiation, and
establishment of robust memory cells.
Memory T cells are long-lived cells that allow for an
eﬃc i e n ta d a p t i v ei m m u n er e s p o n s eu p o nr e - e x p o s u r et o
a pathogen [47]. Such memory cells can be divided into
two categories depending on their traﬃcking and eﬀector
functions. The eﬀector memory T cells (TEM)a r ef o u n di n
peripheral tissues, can respond rapidly to infections, and are
characterized by the low expression of certain markers such
asCD62L, CCR7, and CD27. Upon antigen recognition, they
immediately produce eﬀector cytokines, such as IFN-γ and
TNF-α, conferring a state of protection [47]. In contrast,
central memory T cells (TCM), which are found mainly in
secondary lymphatic organs such as lymph nodes, express
high levels of the CD26L, CCR7, and CD27 markers, and are
slow to exhibit their eﬀector functions. An important goal of
any vaccination protocol would be the induction of both sets
of CD8+ T-cell memory [48].
Another critical factor to consider in T-cell activation
focuses on the proﬁle of T-cell immunodominance hierarchy
that a vaccine is likely to induce. With regard to immun-
odominance, epitope-speciﬁc CD8+ T cells can be organized
intoahierarchy,inwhichcertainimmunodominantepitopes
will cause a set of T cells to expand extensively compared to
subdominant epitope-speciﬁc T cells [49]. A CTL response
c o u l db em o r ee ﬀective when generated against a greater
number of epitopes, as it is more diverse and should lead to
t h ef o r m a t i o no faw i d e rn u m b e ro fs p e c i ﬁ cm e m o r yC D 8 +
T-cell populations that can confer protective immunity.
In evaluating the physiological relevance of cross-
priming in vivo to vaccine development, it has been
demonstrated that cross-priming is a robust process that
induces signiﬁcant CTL responses to multiple epitopes, bothJournal of Biomedicine and Biotechnology 3
in viral and tumor models [21]. In a related study, cross-
priming of inactivated ﬂu virus resulted in a broad and
balanced CTL responses compared to live virus. Interest-
ingly, it appears that the ability of an epitope to access
cross-priming may support its immunodominance position
when considering the overall hierarchy [50–52]. During
virus challenge experiments, it was found that an initial
cross-priming with a lymphocytic choriomeningitis virus
(LCMV)-nucleoprotein (NP), that normally cross-primes
CTLs for the NP396 epitope [17], resulted in increasing
the magnitude of NP396 epitope-speciﬁc T cells. Thus,
the immunodominance hierarchy was modiﬁed so that the
NP396 epitope, an immunodominant epitope found within
the LCMV-NP, was favored in a subsequent virus challenge
[50]. These eﬀects were maintained over time and may have
important implications for vaccination protocols such as
the currently administrated inactivated ﬂu vaccines. In this
paper, it was speculated that the initial cross-priming with
LCMV-NPresultedintheenhancedabilityofNP396-speciﬁc
clones, but not the NP205-specifc clones, to expand and out
compete other T-cell clones speciﬁc for epitopes generated
from other proteins [50]. Importantly, these changes only
occurred when cross-priming preceded viral infection and
thus when T-cell frequencies competing for resources were
lower. Such ﬁndings were not observed in the vaccinia
virus model when peptides were used prior to infections to
prime CTL responses [53]. These diverse ﬁndings may be
related to the diﬀerent replication proﬁles of both viruses
considering that vaccinia does not replicate as eﬃciently as
LCMV in mice. It would also be interesting to compare
immunodominance data in a virus challenge experiment
obtained after priming with peptide versus proteins, where
in the latter condition cross-priming is expected to take place
[50, 53].
Finally, with regard to cross-priming and vaccination,
the discovery and development of adjuvants that are able to
regulate cross-presentation is of utmost importance. When
co-administered with an antigen, adjuvants assist in the
generation of an immune response. Adjuvants can elicit their
immune enhancing eﬀects in a variety of ways, including tar-
geting pattern recognition receptors such as toll-like recep-
tors(TLRs)[54].TLRsignalingcanresultinDCmaturation,
leading to upregulated MHC and co-stimulatory molecule
expression,andincreasedprimingofTcellswithouttheneed
for CD4 T-cell help [26, 54–57]. For example, it has been
shownthatthesyntheticTLR9ligand,CpG-ODN(Cytosine-
phosphorothioate-guanine oligodeoxynucleotides), is read-
ilytakenupbyreceptor-mediatedendocytosisandwasfound
toenhanceCTLresponses.Furthermore,theantigen-speciﬁc
primary and secondary expansion of T cells was better
established when TLR9 ligand was cross-linked to the OVA
antigen [55, 58–60].
Thus, based on many models of cross-priming, re-
searchers are logically aiming to develop novel vaccine
vectors that are capable of inducing CTL responses in vivo
by utilizing exogenous antigen delivery. In the latter part of




the Induction of CTL Responses
In vaccination, delivering exogenous antigens via cross-
presentation should ideally induce both humoral and CTL
responses to improve eﬀectiveimmunity. Asthemajor pAPC
in vivo, DCs are able to stimulate na¨ ıve CD8+ T cells and
are important when considering precise targeting of delivery
vectors. A key area of research involves the modiﬁcation of
vector surfaces with ligands for DC receptors, such as TLR
ligands, as well the application of natural substances that
can allow for eﬀective immune modulation. For example,
the active metabolites of vitamin D3 can inﬂuence adaptive
immune responses to peripherally administered antigens
during vaccination/infection. In these experiments, the abil-
ity of murine DCs to migrate from skin sites of vaccination
to mucosal lymphoid organs seem to be dependent on
the production of active vitamin D3 metabolites produced
locally at the vaccination site, which was associated with
the application of speciﬁc TLR (TLR3/TLR4) ligands [61,
62]. These ﬁndings support previous studies, which demon-
strated that both systemic and common mucosal immune
responses developed in adult mice upon administration of
a subcutaneous or intradermal vaccine containing active
v i t a m i nD 3[ 63]. Thus, vitamin D3 and its metabolites may
represent potential novel adjuvant preparations.
Generally, vaccines should induce eﬀective protective
CTL immunity, and the production of immunological mem-
ory. Potent CTL responses have been reported to be limited
to live attenuated viral or bacterial vaccines [48]. However,
the use of such vaccines is oﬀset by the risk of reinitiating
virulence. Thus, a key target of novel vectors, such as
virus-like particles, microparticles, and archaeosomes, is to
eﬃciently access the cross-presentation pathway. As a result,
these vectors will induce CTL eﬀector and memory T-cell
responses without risking the health of the host. Such vectors
have shown interesting immunological properties, discussed
below, that enable them to be potent in inducing cross-
priming.
4.1. Virus-Like Particles. Virus-like particles (VLPs) are
formedfromviralstructuralproteinsthatlackaviralgenome
and thus assemble into nonreplicative particles [64, 65].
VLPs are safe, stable, and extremely immunogenic due to
their highly repetitive molecular structures [64, 65]. In
addition to their highly immunogenic nature, VLPs can
be easily modiﬁed to increase their immunogenicity by
packaging CpGs into the core antigen particle, which results
in higher frequencies of peptide-speciﬁc CD8+ T cells being
induced [66].
Since VLPs are exogenously acquired by pAPCs, they
are able to use the cross-presentation pathway [67–69]a n d
can induce both CTL and memory responses [70]. For
example,arecombinantparvovirus-(PPV-)VLP,encodinga
knownLCMVCD8+T-cellepitope,wasabletostimulatethe
immune system up to 8 months after the last immunization
[65]. This long-lasting eﬀect was characterized by protection
against a lethal viral (LCMV) infection, in addition to4 Journal of Biomedicine and Biotechnology
responses against peptide-coated or virus-infected target
cells [65]. The high particulate nature of PPV-VLPs was
hypothesized to be associated with its optimal delivery to
the MHC-class I antigen presentation pathway, resulting in
high immunogenicity [65]. This ability to induce CTLs via
cross-priming was demonstrated in another study with HIV
p55gag-VLPs immunizations [70]. In this study, immunized
a n i m a l sw e r ee ﬃciently primed (>8.5 months) for p55gag-
speciﬁc CTL responses that recognized multiple HIV p55gag
epitopes. Altogether, these studies demonstrate that VLPs
are able to prime strong MHC-I restricted CD8+ T-cell
responses through cross-presentation.
The exact mechanism of cross-presentation is not fully
deﬁned; however, recent data suggests that the processing
pathway involving VLPs may vary according to the type of
vector employed. For example, cross-presentation of papaya
mosaic VLPs, which induces robust CTL responses [71], was
proteasome independent [67]. In the case of parvovirus-like
particles (PPV-VLPs) without adjuvant, exogenous antigen
was localized in the late endosomes of DCs [72]. It is
important to note that presence of potential adjuvants,
such as TLR ligands [39], enhances the eﬃciency of cross-
presentation as it allows for the relocation of the TAP
molecules to the early endosomes. As one would expect, the
processing of the PPV-VLPs required vacuolar acidiﬁcation,
proteasome activity, and TAP translocation, but not MHC
class I molecule recycling. Altogether, the data shows that
thecross-presentationofPPV-VLPsoccursviaanendosome-
to-cytosol processing pathway [72]. Interestingly, the uptake
and capture of PPV-VLPs involved macropinocytosis and
lipid rafts participation.
In contrast when employing hepatitis B virus (HBV)
V L P s ,i tw a sf o u n dt h a te ﬃcient CTL cross-priming by DCs
occurred either in a TAP-dependent or TAP-independent
manner [69]. The HBV (VLPs) are also taken up by
macropinocytosis, but rely on endosomal processing and
recycling MHC I molecules in DCs [73].
Thus it may be necessary to evaluate each VLP type
independently, as each vector will have a unique nature
that may be closely associated with the protection it can
elicit against its targeted pathogen or disease. It is also
important to note that not all VLPs are able to activate
pAPCs by themselves. This was highlighted by data showing
that a CTL epitope from LCMV (p33-VLPs) was eﬃciently
processed for MHC class I presentation but induced weak
CTL responses [66]. The CTL response failed to mediate
eﬀective protection from viral challenge in the absence of
external substances that activate APCs, such as anti-CD40
antibodies or CpG oligonucleotides, which engage TLR9
[66]. Clearly, further research is required to fully optimize
this technology, however, VLPs represent a promising avenue
for vector development. Recently, a novel approach utilized
HIV-1 VLPs of a mutant HIV-1 Nef, which acts as an
anchoring element for foreign proteins. Immunization with
such VLPs incorporating a HPV-16 E7 protein, fused to
the mutant HIV-1 Nef, resulted in an robust anti-E7
CD8+ T-cell response, and protection against an HPV-E7
expressing tumour [74]. Furthermore, it was suggested that
co-inoculation of VLPs with diverse epitopes of the same
pathogen could be used to generate CTLs with a wider range
of speciﬁcities to attain enhanced protection [74].
4.2. Microspheres (MSs). Microspheres (MSs) are composed
of biodegradable polymers, such as poly (lactic acid) (PLA),
poly(glycolic acid) (PGA), and polylactic-co-glycolic acid
(PLGA) [75], and can be formed through processes such as
solvent evaporation or spray drying [54, 75]. Depending on
their diameter, loaded MSs can be taken up by APCs through
phagocytosis [76]. This uptake could be also enhanced
due to the depot formation at the site of injection [54].
MSs can be administered orally because they can protect
their cargo including adjuvants (e.g., CpG-ODNs) from
enzyme-mediateddegradation[77].Uponhydrolysisoftheir
polymericbondsbyphagosomalenzymesafterphagocytosis,
the MS polymers are disrupted, causing the release of the
encapsulated antigen [54].
Biodegradable microspheres (MSs) are useful to micro-
encapsulate antigens alone or combined with adjuvants.
Their ability to allow for the controlled release of the antigen
ortoallowfortheformationofadepotatthesiteofinjection
is particularly useful [78]. Poly (D, L-lactide-co-glycolide)
(PLGA) has been used to prepare microspheres that possess
tremendous potential to release encapsulated antigens in a
controlled manner, thus facilitating the protection of the
antigen cargo from immediate degradation in vivo [79]. A
key advantage of MSs is the ﬂexibility in their design, which
allows for a variety of possibilities in combining diﬀerent
antigens and adjuvants. Moreover, speciﬁc cell targeting is
feasible through the addition of ligands to the vehicle surface
that are able to speciﬁcally bind receptors on the surface of
the targeted cell type [78, 79].
MSs can deliver exogenous antigens to the cross-
presentation pathway, but appear to require additional
signals, such as adjuvants, to trigger a CTL response [80].
This process may involve T-cell help which can be provided
via CD40L interactions on helper T cells, and is needed to
promote the costimulatory activation state of DCs required
foroptimalcross-priming[81,82].AsMSsareunabletotrig-
ger DC maturation by themselves [83], cross-presentation
of antigens by immature DCs can result in T-cell ignorance
[43].
Dataexaminingthisphenomenonconcurthatadditional
help signals are required to enhance the cross-priming of
MSs. For example, MSs encapsulating an antigen with an
immunodominant CD8+ T-cell epitope (B-OVAp) failed
to induce antigen-speciﬁc cross-priming of CD8+ T cells,
unlessrecombinantPPV-VLPwereco-injected,whichserved
as an adjuvant to induce a potent CTL response [80].
Interestingly, the PPV-VLPs enhanced this CTL response
in MHC class II
−/− and CD40
−/− mice indicating that the
CD4+ T-cell help was bypassed under these conditions.
Furthermore, such adjuvant activity did not require TLR2,
TLR4, or TLR9 stimulation.
In accordance, recent research has focused on examining
the inﬂuence of adjuvants on cross-priming within the
antigen-containing MSs. These studies used OVA incorpo-
rated into MSs and examined cross-primed antigen-speciﬁcJournal of Biomedicine and Biotechnology 5
T cells by the secretion of IFN-γ in peptide speciﬁc assays
[60, 84]. The CTL response elicited when TLR ligands
were coencapsulated with OVA was stronger compared with
OVA-MS alone or if antigen and adjuvants were separately
encapsulated.
In a study examining the coencapsulation of OVA and a
TLR9 ligand (CpG-ODN), the authors found that both OVA
and CpG-ODN were translocated into lysosomal-associated
membrane protein-1 (Lamp1)-positive phago-endosomal
compartments of DC [60]. The processed OVA peptides on
MHC class I and II molecules on DCs allowed for robust
antigen-speciﬁc CD4+ and CD8+ T-cell proliferation that
were TLR9-dependent [60]. The processing route for MHC-
I antigen presentation in this study required endosomal
acidiﬁcation, TAP translocation, and proteasomal processing
[60]. In a separate study, it was found that CpG-ODN in
the MSs induced DC maturation, characterized by increased
MHC and co-stimulatory molecule expression, which may
have aided the increased cross-priming [84]. In both reports
[60, 84], induction of OVA speciﬁc Tcells, especially after
boosting, was comparable to what is observed when live
vectors encoding OVA are employed [85, 86]. In addition,
the induced immunity was protective against a challenge of
L. monocytogenes, vaccinia virus and protected against OVA
expressing tumors [60, 84].
However, including adjuvant activity with the antigens
is not limited solely to MSs. For example, liposomes are
vesicles composed of lipid bilayers that are separated by
aqueous regions, and are comparable to MSs as they are
also biodegradable and safe, making them attractive vectors
for vaccine delivery [75, 87]. Liposomes were one of the
early vectors developed in order to co-deliver adjuvants, such
as CpG ODN, and antigens [87], and have been used in
therapy of diseases such as leishmaniasis [88]. In addition,
the adjuvant eﬀects of liposomes complexed to TLR agonists
were found to induce eﬀective CD4+ and CD8+ T-cell
responses against peptide and protein antigens. In particular
TLR3 or TLR9 agonists eﬀectively cross-primed CD8+ T-cell
responses independently of CD4+ T-cell help [56].
Nonetheless, despite the advantages of using MSs in
vaccine delivery, additional data explaining the exact pro-
cessing mechanisms is needed. In addition, further research
is required to reveal how this generates protective potential
when applying diﬀerent antigenic determinants in diﬀerent
infections models. Regardless, the simultaneous inclusion of
antigen and adjuvant appears to hold promise to optimize
future vaccination strategies that use MSs.
4.3. Archaeosomes. A r c h a e o s o m e sa r ean o v e lg e n e r a t i o n
of liposomes that are composed of the polar lipids of
Archaea, which leads to immune-stimulating interactions
with APCs. The archeal lipid cores oﬀer archaeosomes long-
lasting stability at a variety of environmental extremes,
including temperature, pH, and oxidative conditions. These
properties allow them to induce strong memory responses
and avoid fusion or aggregation, thus reducing antigen
leakage[89].Theentrapmentofantigeninarchaeosomeshas
been documented to facilitate MHC-I cross-presentation,
resulting in the activation of long-lived CD8+ T-cell immu-
nity [85, 89–91]. For example, a single immunization with
a Methanobrevibacter smithii-OVA (M. smithii) archaeosome
was found to prime 2–5% of antigen-speciﬁc T cells by day 7,
while boosting on day 21 resulted in an expansion to about
20% [85]. Furthermore, after two immunizations of low
doses M. smithii-OVA archaeosomes, re-stimulated spleen
cell eﬀectors were able to exhibit strong cytolytic activity of
targetcellslabeledwiththespeciﬁcpeptides[92].Thisability
to activate CTLs with archaeosomes was demonstrated in
CD4−/− [93] and IL-12−/− mice [92].
When examining the quality of archaeosome-primed
CD8+ T-cell responses, it was reported that the responses
were superior in magnitude to other particulate vesicular
systemssuchasliposomes[90].Inaddition,asingleinjection
of the vector induced a profound primary response, leading
to the formation of around 1% of CD8+ TCM which
exhibited a phenotype (CD44++CD62L++) typical of the
central memory cells [85]. The responses were comparable
to vaccination with live vectors encoding OVA such as L.
monocytogenes vector [85] and induced protective CD8+ T-
cells responses that were TLR2-independent.
Unlike the MSs delivery system that we discussed above,
archaeosomescantargetantigenforcross-presentationwhile
simultaneously activating pAPC, thus allowing for proper
induction of co-stimulatory molecules and cytokine pro-
duction [89]. OVA entrapped in M. smithii is the best-
characterized model with respect to studying the mech-
anisms of archaeosome cross-presentation. Due to the
presence of exposed archaetidylserine head groups on their
surfaces, M. smithii archaeosomes are taken up by receptor-
mediated endocytosis [91]. Thus, they are able to utilize
the same pathway that relies on the phosphatidylserine (PS)
receptor-mediated clearance of apoptotic cells by pAPCs
[91]. However, after phagocytosis, it was seen that the
presentation of archaeosomal-antigens on MHC-I relied on
cytosolic proteasomal processing and TAP-activity. Interest-
ingly, it was demonstrated that the blocking of endosomal
acidiﬁcation resulted in the block of MHC I processing,
which can be due to the fact that acidiﬁcation in the
endosomesorphagolysosomeshelpsantigenescapefromthe
archaeosomes [91].
It is important to note that other archaeosome types
lacking PS are also phagocytosed eﬃciently and can induce
strong CD8+ T-cell immunity [89]. Thus, diﬀerent archaeo-
some vectors can be expected to rely on diﬀerent receptors
for cellular entry. Overall, archaeosomes provide promise to
the ﬁeld of vaccine development, and appear to represent
versatile, potentially universal vectors. This research ﬁeld can
only beneﬁt from the involvement and collaboration of more
research groups.
5. Conclusion
The majority of vaccines utilized in the past were attenuated
vaccine strains and, although critical in the prevention
of several infectious diseases, the inherent risk that they
carry necessitates the development of alternative vaccines.6 Journal of Biomedicine and Biotechnology
Table 1: Summary of the diverse vector approaches used for the generation of CTLs.
Vector Outcome Ref
VLP - Recombinant porcine
parvovirus encoding LCMV-NP
- Strong CTL responses without a need for adjuvant, the CTL activity persisted in vivo
for 8 months [65]
- Complete protection against lethal LCMV infection
VLP - HIV-p55gag-VLP - Without adjuvant, long lived CTL responses against multiple HIV-1 p55gag epitopes
were detected [70]
VLP - Papaya mosaic VLP
(LCMV-GP33)
- Immunized mice develop GP33-speciﬁc CTLs, which rapidly expanded post-LCMV
challenge and enhanced the protection against LCMV infection in dose-dependent
manner
[67]
VLP - HBV-VLP (LCMV-GP33) - TAP-deﬁcient DC and macrophages mediated cross-presentation of GP33 in vivo and
in vitro [69]
VLP- VSV encoding HPV-16
E7protein




- Results in the priming of potent CTL responses in CD4 and CD40-independent manner [80]
- Protective CTL against the OVA-bearing melanoma
Microsphere - PLGA-MSs - Vaccination enhanced CTL responses when OVA was coencapsulated with CpG or
polyI:C [84]
- Single immunization with coencapsulated MS-OVA-CpG induced eﬃcient CTLs and
protected against infection with OVA-expressing vaccinia virus
- Clonal expansion of primary and secondary antigen-speciﬁc CD4 and CD8 T cells [60]
- Potency demonstrated by protective immune responses to either infection or tumors
Liposomes -liposome-Ag-nucleic
acid complexes (LANAC)
- TLR3 or TLR9 were able to enhance CTL cross-priming independent of CD4+ T-cell
help
[56]
- Antigen-speciﬁc CD8+ T cells were functionally active and persisted for long periods in
tissues
-E ﬀective immunity against B16 tumors and M. tuberculosis
Archaeosome (M. smithii)-
Encoding OVA
- Single injection evoked profound primary CTL response
[85] - Recall response observed >300 days
- Protective CD8+ T cells induced in TLR2-deﬁcient mice
- Resisted tumor growth of B16OVA melanoma cells [92]
- Enhanced CTL responses in the absence of IL-12 and IFN-γ
- CTL activity was undetectable in perforin-deﬁcient mice
[93] -L o n g - t e r mr e s p o n s e si nC D 4 +Tc e l ld e ﬁ c i e n tm i c e
- Potent memory CTL response to OVA lasting for ≥154 days
The advent of nonreplicating vaccine vectors (key ﬁndings
summarized in Table 1) has revealed the importance of
eﬃciently targeting exogenously derived antigens to immune
cells, which would allow for the cross-priming of CD8+
T cells rather than cross-tolerance. The attractiveness of
this mechanism is oﬀset by the need to optimize such
vectors, in order to maximize the immune response. In
order to achieve this goal, more research is needed to
dissect the cellular and molecular factors that regulate cross-
presentation events during the initiation of CTL immune
responses. We have come far since the observations made
by Edward Jenner and the ﬁeld is now ripe for developing
novel vaccine-adjuvant complexes to make the next step
forward that improves on the initial discovery of the small
pox vaccine.
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